Rise Gold Corp. (RYES)

Inozyme Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is August - July.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 8, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021	Jul 31, 2020
Market Capitalization	16	7	6	12	14	17
Market Cap Growth	-56.35%	25.90%	-50.60%	-13.90%	-19.76%	81.08%
Enterprise Value	15	8	6	12	13	17
Last Close Price	0.17	0.13	0.15	0.36	0.52	0.65
PB Ratio	6.01	3.12	1.65	3.32	3.25	3.41
P/TBV Ratio	6.01	3.12	1.65	3.32	3.25	3.41
Debt / Equity Ratio	0.50	0.75	0.40	0.38	0.23	0.15
Quick Ratio	1.14	0.10	1.65	1.59	4.09	6.87
Current Ratio	1.28	0.34	1.93	2.82	5.79	7.61
Return on Equity (ROE)	-97.97%	-119.86%	-102.09%	-88.13%	-34.41%	-118.50%
Return on Assets (ROA)	-20.33%	-37.46%	-36.64%	-34.31%	-27.05%	-29.23%
Return on Capital (ROIC)	-25.05%	-44.21%	-41.68%	-38.91%	-35.27%	-38.97%
Earnings Yield	-17.12%	-48.06%	-62.11%	-29.04%	-11.58%	-31.69%
FCF Yield	-	-29.83%	-42.02%	-22.59%	-20.60%	-17.76%
Buyback Yield / Dilution	-31.83%	-29.13%	-22.11%	-11.53%	-22.38%	-47.58%

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.